Dr. Jacqueline Huang Shared on the Methodology of Business Valuation for Biotech 黃瑋博士分享關於生物科技公司的估值方法

2020年2月，黃瑋博士獲邀前往深圳坪山的生物科技中心演講，分享有關生物科技公司商業評估的資訊。黃瑋博士深入分析該行業的特性—涉及高風險、長時間、巨額的資本投資，且受國家醫藥機構嚴格監管，由此引入主題，探討生物科技公司的融資渠道、上市條件，以及估值方法，強調公司所處的生命週期不同，所應用的估值模型也有所不同。參考一家致力於開發創新藥品的公司作為案例，黃瑋博士進一步說明估值過程中所牽涉的假設、模型及其他重要考量，引起與會人士熱烈討論。

In February of 2020, Dr. Jacqueline Huang had delivered a speech on business valuation for Biotech companies in Shenzhen Pingshan Biotechnology Centre. Dr. Jacqueline Huang had first analyzed the characteristics of the industry – involving highly-risky, long-term and huge capital investments, and stringently monitored by national pharmaceutical authorities, thereby leading into the topic, discussing the financing channels, listing requirements and valuation methods for Biotech companies, with emphasis on the choice of valuation model with respect to the stages within the company lifecycle. Referring to a drug company as a case study, Dr. Jacqueline Huang had further elaborated on the assumptions, models and other critical factors in relation to the valuation processes, provoking conversations of the audience.